Apimeds: Majority stockholder consent to remove directors/officers is null and void

Apimeds Pharmaceuticals US, Inc.

Inscobee Inc. and Apimeds, Inc. attempted written consent to remove directors Kogan, Koo, O’Donnell, Weintraub and officers Menon (CEO) and Frim (CFO).
Company determined consent invalid due to violations of irrevocable proxy, consent waiver, and anti-frustration covenant in Support Agreement.
Support Agreement expressly states any action taken in violation is null and void; consent void ab initio.
Company will proceed with actions described in Schedule 14C Information Statement filed Feb 27, 2026, mailed March 5, 2026.
This Amendment No. 1 clarifies the previously reported actions are of no force or effect.

item 5.02item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.